Literature DB >> 18026799

Prognostic significance of the immediate early response gene X-1 (IEX-1) expression in pancreatic cancer.

Tetsuro Sasada1, Koichi Azuma, Tatsuya Hirai, Hiroki Hashida, Michiyuki Kanai, Takashi Yanagawa, Arimichi Takabayashi.   

Abstract

BACKGROUND: The immediate early response gene X-1 (IEX-1) is a stress-inducible protein that is involved in the regulation of cell proliferation and apoptosis. The aim of this study was to evaluate the prognostic significance of IEX-1 expression in pancreatic cancer.
METHODS: IEX-1 protein expression was examined on paraffin-embedded specimens from 78 patients with pancreatic ductal adenocarcinoma using immunohistochemistry. The relationships between the IEX-1 expression and other clinicopathological parameters and patient survival were evaluated. A similar analysis was conducted in a subgroup of 48 patients, who underwent a macroscopically curative resection with detailed information on the pathological findings.
RESULTS: Among 78 pancreatic cancer patients, 41 patients (53%) were positive for IEX-1 staining. In a multivariate analysis, curative operation (P < .001), pathological stage I-III (P = .001), and positive IEX-1 expression (P = .002) were significantly favorable factors for survival. In a subgroup of 48 patients undergoing a macroscopically curative surgery, IEX-1 expression was positive in 28 patients (58%). A significant negative correlation was observed between the IEX-1 expression and serosal (P = .032) or arterial (P = .040) invasion of tumors. A multivariate analysis demonstrated limited local invasion (pT1-3, P = .021), negative lymph node involvement (pN0, P < .001), and positive IEX-1 expression (P = .004) to be significantly favorable factors for survival.
CONCLUSIONS: The positive IEX-1 expression in tumor tissues may be associated with a better prognosis in pancreatic cancer. An immunohistochemical assessment of IEX-1 expression may therefore be helpful for predicting patient prognosis in this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18026799     DOI: 10.1245/s10434-007-9669-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  18 in total

1.  IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation.

Authors:  Maria Noé Garcia; Daniel Grasso; Maria Belen Lopez-Millan; Tewfik Hamidi; Celine Loncle; Richard Tomasini; Gwen Lomberk; Françoise Porteu; Raul Urrutia; Juan L Iovanna
Journal:  J Clin Invest       Date:  2014-09-24       Impact factor: 14.808

2.  Selective single cell isolation for genomics using microraft arrays.

Authors:  Joshua D Welch; Lindsay A Williams; Matthew DiSalvo; Alicia T Brandt; Raoud Marayati; Christopher E Sims; Nancy L Allbritton; Jan F Prins; Jen Jen Yeh; Corbin D Jones
Journal:  Nucleic Acids Res       Date:  2016-08-16       Impact factor: 16.971

3.  Modulation of nuclear factor E2-related factor-2 (Nrf2) activation by the stress response gene immediate early response-3 (IER3) in colonic epithelial cells: a novel mechanism of cellular adaption to inflammatory stress.

Authors:  Imke Stachel; Claudia Geismann; Konrad Aden; Florian Deisinger; Philip Rosenstiel; Stefan Schreiber; Susanne Sebens; Alexander Arlt; Heiner Schäfer
Journal:  J Biol Chem       Date:  2013-12-05       Impact factor: 5.157

4.  Resistance of Sézary cells to TNF-α-induced apoptosis is mediated in part by a loss of TNFR1 and a high level of the IER3 expression.

Authors:  Oleg E Akilov; Mei X Wu; Irina V Ustyugova; Louis D Falo; Larisa J Geskin
Journal:  Exp Dermatol       Date:  2012-04       Impact factor: 3.960

5.  Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes.

Authors:  David P Steensma; Jessemy D Neiger; Julie C Porcher; J Jonathan Keats; P Leif Bergsagel; Thomas R Dennis; Ryan A Knudson; Robert B Jenkins; Rafael Santana-Davila; Rajiv Kumar; Rhett P Ketterling
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

6.  Ablation of gly96/immediate early gene-X1 (gly96/iex-1) aggravates DSS-induced colitis in mice: role for gly96/iex-1 in the regulation of NF-kappaB.

Authors:  Christian Sina; Alexander Arlt; Philip Rosenstiel; Heiner Schäfer; Olga Gavrilova; Emilie Midtling; Marie-Luise Kruse; Susanne Sebens Müerköster; Rajiv Kumar; Ulrich R Fölsch; Stefan Schreiber
Journal:  Inflamm Bowel Dis       Date:  2010-02       Impact factor: 5.325

Review 7.  Immediate early response gene X-1, a potential prognostic biomarker in cancers.

Authors:  Mei X Wu; Irina V Ustyugova; Liping Han; Oleg E Akilov
Journal:  Expert Opin Ther Targets       Date:  2013-02-04       Impact factor: 6.902

8.  Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma.

Authors:  Giuseppe Aprile; Claudio Avellini; Michele Reni; Micol Mazzer; Luisa Foltran; Diego Rossi; Stefano Cereda; Emiliana Iaiza; Gianpiero Fasola; Andrea Piga
Journal:  Tumour Biol       Date:  2012-09-25

9.  Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis.

Authors:  Tewfik Hamidi; Hana Algül; Carla Eliana Cano; Maria José Sandi; Maria Inés Molejon; Marc Riemann; Ezequiel Luis Calvo; Gwen Lomberk; Jean-Charles Dagorn; Falk Weih; Raul Urrutia; Roland Michael Schmid; Juan Lucio Iovanna
Journal:  J Clin Invest       Date:  2012-05-08       Impact factor: 14.808

10.  Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.

Authors:  Winnie S Liang; David W Craig; John Carpten; Mitesh J Borad; Michael J Demeure; Glen J Weiss; Tyler Izatt; Shripad Sinari; Alexis Christoforides; Jessica Aldrich; Ahmet Kurdoglu; Michael Barrett; Lori Phillips; Hollie Benson; Waibhav Tembe; Esteban Braggio; Jeffrey A Kiefer; Christophe Legendre; Richard Posner; Galen H Hostetter; Angela Baker; Jan B Egan; Haiyong Han; Douglas Lake; Edward C Stites; Ramesh K Ramanathan; Rafael Fonseca; A Keith Stewart; Daniel Von Hoff
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.